Multiple guide RNA
By using Csy4 endonuclease cleavage technology in longer RNA transcripts, the efficient production of multiple functional gRNAs in mammalian cells is achieved, and the lack of gRNA activity in the RNA polymerase II promoter in the prior art is solved. The problem has improved the multiple editing capabilities of Cas9 nuclease.
Patent Information
- Application Number
- CN202110920229.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2014-04-23
- Filing Date
- 2014-09-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2034-09-18
AI Technical Summary
The prior art is difficult to effectively express multiple guide RNAs in mammalian cells, especially to cleave functional gRNAs from longer mRNA transcripts expressed by the RNA polymerase II promoter, resulting in limited multiple applications of Cas9 nucleases.
Csy4 endonuclease recognizes short RNA hairpin sequences, and multiple gRNA sequences are cleaved from longer RNA transcripts and flanked them as Csy4 cleavage sequences to form a polybox structure, thereby achieving multiple expression and Highly active gRNA production.
It realizes the efficient expression of multiple functional gRNAs in mammalian cells, improves the activity and multiple editing capabilities of Cas9 nuclease, solves the limitations of gRNA expression of a single RNA polymerase III promoter, and allows the RNA polymerase II promoter to be produced from the RNA polymerase II promoter. The flanking of the made mRNA is excised to produce functional gRNA.
Smart Images

Figure CN113684205B_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 201480076396.6. The application date of the original application 201480076396.6 is September 18, 2014, and its name is “Multiple Guide RNA”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of Provisional Patent Application No. 61 / 921,007, filed December 26, 2013; Provisional Patent Application No. 14 / 211,117, filed March 14, 2014; PCT / US 2014 / 029068, filed March 14, 2014; PCT / US 2014 / 028630, filed March 14, 2014; PCT / US 2014 / 035162, filed March 23, 2014; and PCT / US 2014 / 029304, filed March 14, 2014. All of the above are incorporated herein by reference.
[0004] Federally funded research or development
[0005] This invention was made with government support under Grant No. DP1 GM105378 awarded by the National Institutes of Health. The government has certain rights in this invention. Technical Field
[0006] Described are methods and constructs for multiplexed expression of highly active CRISPR guide RNAs (gRNAs) from RNA polymerase II and III promoters, optionally in mammalian cells. background
[0007] The Cas9 nuclease forms a programmable RNA-guided clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) system (Wiedenheft et al., Nature 482, 331-338 (2012); Horvath et al., Science 327, 167-170 (2010); Terns et al., Curr Opin Microbiol 14, 321-327 (2011)) that can be used to generate site-specific breaks in target DNA sequences in vitro, in mammalian cells, and in living model organisms such as zebrafish (Wang et al., Cell 153, 910-918 (2013); Shen et al., Cell Res (2013); Dicarlo et al., Nucleic Acids Res (2014)). Acids Res) (2013); Jiang et al., Nat Biotechnol 31, 233-239 (2013); Jinek et al., Elife 2, e00471 (2013); Hwang et al., Nat Biotechnol 31, 227-229 (2013); Cong et al., Science 339, 819-823 (2013); Mali et al., Science 339, 823-826 (2013c); Cho et al., Nat Biotechnol 31, 230-232 (2013); Gratz et al., Genetics 194(4): 1029-35 (2013)).A short, approximately 100 nt guide RNA (gRNA) complexes with Cas9 and directs the nuclease to a specific target DNA site; targeting is mediated by a sequence of at least 17-20 nucleotides (nt) at the 5' end of the gRNA that is designed to interact via simple base pair complementarity between the first 17-20 nucleotides of the engineered gRNA and the complementary strands of the target genomic DNA sequence of interest immediately adjacent to a protospacer sequence adjacent motif (PAM), such as a PAM matching the sequence NGG or NAG (Shen et al., Cell Res (2013); Dicarlo et al., Nucleic Acids Res (2013); Jiang et al., Nat Biotechnol 31, 233-239 (2013); Jinek et al., Elife Biotech 31, 234-239 (2013); 2, e00471 (2013); Hwang et al., Nat Biotechnol 31, 227-229 (2013); Cong et al., Science 339, 819-823 (2013); Mali et al., Science 339, 823-826 (2013c); Cho et al., Nat Biotechnol 31, 230-232 (2013); Jinek et al., Science 337, 816-821 (2012)). gRNA can also guide a catalytically inactive Cas9 protein (referred to as dCas9, see Jinek et al., Science 337:816–821 (2012)), which in turn is fused to an effector domain (e.g., a transcriptional activation domain), see, e.g., USSN 61 / 799,647, filed March 15, 2013, and 61 / 838,148, filed June 21, 2013, both of which are incorporated herein by reference. The latter system enables RNA-guided recruitment of heterologous effector domains to genomic loci of interest.
[0008] Overview
[0009] The present invention is based at least in part on the discovery of Csy4, an endoribonuclease that recognizes short RNA hairpin sequences and can be used to excise a multifunctional gRNA (generated from an RNA pol II or III promoter) encoded on a single longer RNA transcript, in which each gRNA is separated by a Csy4 cleavage site.
[0010] Therefore, in a first aspect, the present invention provides a deoxyribonucleic acid (DNA) molecule comprising a plurality of sequences encoding guide RNAs (gRNAs), wherein each gRNA is flanked by at least one Csy4 cleavage sequence comprising or consisting of the sequence GTTCACTGCCGTATAGGCAG (SEQ ID NO: 1) or GTTCACTGCCGTATAGGCAGCTAAGAAA (SEQ ID NO: 2).
[0011] In some embodiments, the DNA molecule is operably linked to a promoter sequence.
[0012] In some embodiments, the DNA molecule comprises two, three, or more gRNA sequences, each of which is flanked by at least one Csy4 cleavage sequence.
[0013] In some embodiments, the promoter sequence is an RNA polymerase II (Pol II) promoter or a Pol III promoter, preferably an RNA Pol II promoter. In some embodiments, the Pol II promoter is selected from the group consisting of CAG, EF1A, CAGGS, PGK, UbiC, CMV, B29, desmin, endoglin, FLT-1, GFPA, and SYN1 promoters.
[0014] On the other hand, the invention provides DNA molecule, this DNA molecule comprises the promoter sequence connected to one, two, three or more boxes, these boxes comprise: the sequence of coding guide RNA, i.e. the sequence of about 100nt, for example 95-300nt, for example 95-105nt for the system based on Streptococcus pyogenes, this sequence is connected to the Csy4 cleavage site, for example SEQ ID NO:1 or 2.
[0015] In some embodiments, the DNA molecule includes a Pol II promoter, which is operably connected to a first sequence encoding a first guide RNA, which is connected to a Csy4 cleavage site, which is connected to a second sequence encoding a second guide RNA, which is connected to a Csy4 cleavage site, which is connected to a third sequence encoding a third guide RNA, which is connected to a Csy4 cleavage site. In some embodiments, an additional guide RNA connected to a Csy4 cleavage site is included. For example, the DNA molecule can have the following structure: promoter-C4-gRNA-C4-gRNA-C4-gRNA-C4 promoter-C4-gRNA-C4-gRNA-C4-gRNA-C4-gRNA-C4 promoter-C4-gRNA-C4-gRNA-C4-gRNA-C4-gRNA-C4 promoter-C4-gRNA-C4-gRNA-C4-gRNA-C4-gRNA-C4-gRNA C4 and so on. In this illustration, C4 is a sequence encoding a Csy4 RNA cleavage site and gRNA is a sequence encoding a guide RNA.
[0016] In some embodiments, the Cas9 sgRNA comprises the following sequence:
[0017] (X 17-20 )GUUUUAGAGCUAUGCUGUUUUG(X N )(SEQ ID NO:4);
[0018] (X 17-20 )GUUUUAGAGCUA (SEQ ID NO:5);
[0019] (X 17-20 )GUUUUAGAGCUAUGCUGUUUUG (SEQ ID NO: 6);
[0020] (X 17-20 )GUUUUAGAGCUAUGCU(SEQ ID NO:7);
[0021] (X 17-20 )GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCG
[0022] (X N )(SEQ ID NO:8);
[0023] (X 17-20 )GUUUUAGAGCUAUGCUGAAAAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUC(X N)(SEQ ID NO:9);
[0024] (X 17-20 )GUUUUAGAGCUAUGCUGUUUUGGAAACAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUC(X N )(SEQ ID NO:10);
[0025] (X 17-20 )GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC(X N )(SEQ ID NO:11),
[0026] (X 17-20 )GUUUAAGAGCUAGAAAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 12);
[0027] (X 17-20 )GUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 13); or
[0028] (X 17-20 )GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 14),
[0029] Where X 17-20 is a sequence complementary to the complementary strand of the target sequence, preferably 17 to 20 consecutive nucleotides of the target sequence immediately 5' to the protospacer adjacent motif (PAM), and X N is any sequence that does not interfere with the binding of RNA to Cas9. Although X is exemplified herein using the Streptococcus pyogenes Cas9 system 17-20 , but longer sequences may also be used, for example, if appropriate for other systems.
[0030] In certain embodiments, the DNA molecule also includes a sequence encoding a functional Csy4 enzyme.
[0031] Also provided here is a carrier that comprises a DNA molecule described herein, for example, optionally comprises a carrier of a sequence of a functional Csy4 enzyme of coding.Also provided here is the multiple transcript produced by these DNA molecule, for example, the complete RNA that is not yet cut with Csy4.
[0032] In yet another aspect, provided herein are methods for producing multiple guide RNAs in cells. These methods include expressing a DNA molecule described herein in a cell.
[0033] In certain embodiments, the cell is a mammalian cell, and the cell also expresses an exogenous functional Csy4 enzyme sequence, or the method further comprises giving a functional Csy4 enzyme or a nucleic acid encoding a functional Csy4 enzyme.
[0034] On the other hand, the invention provides a method for changing the expression of one or more target genes in a cell. These methods include expressing a DNA molecule as described herein, for example, including a DNA molecule encoding a plurality of sequences of a guide RNA (gRNA), wherein each gRNA includes a variable sequence complementary to at least 17-20nt of one or more target genes, and each gRNA flank is at least one Csy4 cleavage sequence, the Csy4 cleavage sequence includes sequence GTTCACTGCCGTATAGGCAG (SEQ ID NO: 1) or GTTCACTGCCGTATAGGCAGCTAAGAAA (SEQ ID NO: 2) or consisting of it.
[0035] In the methods and compositions of the present invention, gRNA can be, as described herein, a single guide RNA including fused tracrRNA and crRNA, or can include only crRNA, and tracrRNA can be expressed from the same or different DNA molecules. Therefore, in some embodiments, the DNA molecules described herein also include sequences encoding tracrRNA. In some embodiments, these methods include expressing separate tracrRNA in cells, such as contacting these cells with vectors or DNA molecules expressing tracrRNA.
[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. These materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.
[0037] Other features and advantages of the invention will be apparent from the following detailed description and drawings, and from the claims. Sequence Listing <110> GE Healthcare <120> Multiple guide RNA <130> 40174-0012CN2 <150> PCT / US2014 / 035162 <151> 2014-04-23 <150> 14 / 211,117 <151> 2014-03-14 <150> PCT / US2014 / 029068 <151> 2014-03-14 <150> PCT / US2014 / 028630 <151> 2014-03-14 <150> PCT / US2014 / 029304 <151> 2014-03-14 <150> 61 / 921,007 <151> 2013-12-26 <150> 61 / 930,782 <151> 2014-01-23 <160> 54 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 1 gttcactgcc gtataggcag 20 <210> 2 <211> 28 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 2 gttcactgcc gtataggcag ctaagaaa 28 <210> 3 <211> 4 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> 3 Gly Gly Gly Ser 1 <210> 4 <211> 342 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <220> <221> Modified bases <222> (43)..(342) <223> a, c, u or g, and the region may include 0-300 nucleotides, some of which may be missing <400> 4 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcuguuu ugnnnnnnnn nnnnnnnnnn 60 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nn 342 <210> 5 <211> 32 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 5 nnnnnnnnnn nnnnnnnnnn guuuuagagc ua 32 <210> 6 <211> 42 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 6 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcuguuu ug 42 <210> 7 <211> 36 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 7 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcu 36 <210> 8 <211> 362 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <220> <221> Modified bases <222> (63)..(362) <223> a, c, u or g, and the region may include 0-300 nucleotides, some of which may be missing <400> 8 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60 cgnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360 nn 362 <210> 9 <211> 375 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <220> <221> Modified bases <222> (76)..(375) <223> a, c, u or g, and the region may include 0-300 nucleotides, some of which may be missing <400> 9 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcugaaa agcauagcaa guuaaaauaa 60 ggcuaguccg uuaucnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360 nnnnnnnnnn nnnnn 375 <210> 10 <211> 387 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <220> <221> Modified bases <222> (88)..(387) <223> a, c, u or g, and the region may include 0-300 nucleotides, some of which may be missing <400> 10 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcuguuu uggaaacaaa acagcauagc 60 aaguuaaaau aaggcuaguc cguuaucnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360 nnnnnnnnnn nnnnnnnnnn nnnnnnn 387 <210> 11 <211> 396 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <220> <221> Modified bases <222> (97)..(396) <223> a, c, u or g, and the region may include 0-300 nucleotides, some of which may be missing <400> 11 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60 cguuaucaac uugaaaaagu ggcaccgagu cggugcnnnn nnnnnnnnnn nnnnnnnnnn 120 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnn 396 <210> 12 <211> 96 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 12 nnnnnnnnnn nnnnnnnnnn guuuaagagc uagaaauagc aaguuuaaau aaggcuaguc 60 cguuaucaac uugaaaaagu ggcaccgagu cggugc 96 <210> 13 <211> 106 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 13 nnnnnnnnnn nnnnnnnnnn guuuuagagc uaugcuggaa acagcauagc aaguuuaaau 60 aaggcuaguc cguuaucaac uugaaaaagu ggcaccgagu cggugc 106 <210> 14 <211> 106 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 14 nnnnnnnnnn nnnnnnnnnn guuuaagagc uaugcuggaa acagcauagc aaguuuaaau 60 aaggcuaguc cguuaucaac uugaaaaagu ggcaccgagu cggugc 106 <210> 15 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <223> Description of Combined DNA / RNA Molecule: Synthetic Oligonucleotide <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 15 nnnnnnnnnn nnnnnnnnnn gttttagagc tagaaa 36 <210> 16 <211> 60 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 16 tagcaagtta aaataaggct agtccgttat caacttgaaa aagtggcacc gagtcggtgc 60 <210> 17 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> 17 Gly Gly Gly Gly Ser 1 5 <210> 18 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> 18 Asp Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu 1 5 10 <210> 19 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> 19 Pro Lys Lys Lys Arg Lys Val Glu Asp Pro Lys Lys Lys Arg Lys Val 1 5 10 15 Asp <210> 20 <211> 1401 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> 20 Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val 1 5 10 15 Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe 20 25 30 Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Asn Leu Ile 35 40 45 Gly Ala Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu 50 55 60 Lys Arg Thr Ala Arg Arg Tyr Thr Arg Arg Lys Asn Arg With Cys 65 70 75 80 Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Asp Ser 85 90 95 Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys 100 105 110 His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr 115 120 125 His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Leu Val Asp 130 135 140 Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His 145 150 155 160 Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro 165 170 175 Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr 180 185 190 Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala 195 200 205 Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn 210 215 220 Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn 225 230 235 240 Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe 245 250 255 Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp 260 265 270 Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp 275 280 285 Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp 290 295 300 Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser 305 310 315 320 Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys 325 330 335 Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe 340 345 350 Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser 355 360 365 Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp 370 375 380 Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg 385 390 395 400 Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 405 410 415 Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe 420 425 430 Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile 435 440 445 Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp 450 455 460 Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu 465 470 475 480 Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr 485 490 495 Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser 500 505 510 Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys 515 520 525 Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln 530 535 540 Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr 545 550 555 560 Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp 565 570 575 Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly 580 585 590 Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp 595 600 605 Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr 610 615 620 Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala 625 630 635 640 His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr 645 650 655 Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp 660 665 670 Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe 675 680 685 Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe 690 695 700 Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu 705 710 715 720 His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly 725 730 735 Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly 740 745 750 Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln 755 760 765 Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile 770 775 780 Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro 785 790 795 800 Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu 805 810 815 Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg 820 825 830 Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys 835 840 845 Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg 850 855 860 Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys 865 870 875 880 Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys 885 890 895 Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp 900 905 910 Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr 915 920 925 Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp 930 935 940 Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser 945 950 955 960 Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg 965 970 975 Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val 980 985 990 Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe 995 1000 1005 Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala 1010 1015 1020 Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe 1025 1030 1035 Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala 1040 1045 1050 Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu 1055 1060 1065 Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val 1070 1075 1080 Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr 1085 1090 1095 Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys 1100 1105 1110 Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro 1115 1120 1125 Light Light Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val 1130 1135 1140 Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys 1145 1150 1155 Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser 1160 1165 1170 Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys 1175 1180 1185 Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu 1190 1195 1200 Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly 1205 1210 1215 Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val 1220 1225 1230 Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser 1235 1240 1245 Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys 1250 1255 1260 His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys 1265 1270 1275 Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala 1280 1285 1290 Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn 1295 1300 1305 Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala 1310 1315 1320 Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser 1325 1330 1335 Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr 1340 1345 1350 Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp 1355 1360 1365 Ala Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser Leu Gly Ser Gly 1370 1375 1380 Ser Pro Lys Lys Lys Arg Lys Val Glu Asp Pro Lys Lys Lys Arg 1385 1390 1395 Lys Val Asp 1400 <210> twenty one <211> 1368 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> twenty one Met Asp Lys Lys Tyr Ser Ile Gly Leu Ala Ile Gly Thr Asn Ser Val 1 5 10 15 Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe 20 25 30 Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Asn Leu Ile 35 40 45 Gly Ala Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu 50 55 60 Lys Arg Thr Ala Arg Arg Tyr Thr Arg Arg Lys Asn Arg With Cys 65 70 75 80 Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Asp Ser 85 90 95 Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys 100 105 110 His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr 115 120 125 His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Leu Val Asp 130 135 140 Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His 145 150 155 160 Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro 165 170 175 Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr 180 185 190 Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala 195 200 205 Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn 210 215 220 Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn 225 230 235 240 Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe 245 250 255 Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp 260 265 270 Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp 275 280 285 Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp 290 295 300 Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser 305 310 315 320 Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys 325 330 335 Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe 340 345 350 Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser 355 360 365 Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp 370 375 380 Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg 385 390 395 400 Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu 405 410 415 Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe 420 425 430 Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile 435 440 445 Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp 450 455 460 Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu 465 470 475 480 Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr 485 490 495 Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser 500 505 510 Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys 515 520 525 Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln 530 535 540 Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr 545 550 555 560 Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp 565 570 575 Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly 580 585 590 Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp 595 600 605 Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr 610 615 620 Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala 625 630 635 640 His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr 645 650 655 Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp 660 665 670 Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe 675 680 685 Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe 690 695 700 Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu 705 710 715 720 His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly 725 730 735 Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly 740 745 750 Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln 755 760 765 Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile 770 775 780 Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro 785 790 795 800 Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu 805 810 815 Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg 820 825 830 Leu Ser Asp Tyr Asp Val Asp Ala Ile Val Pro Gln Ser Phe Leu Lys 835 840 845 Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg 850 855 860 Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys 865 870 875 880 Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys 885 890 895 Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp 900 905 910 Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr 915 920 925 Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp 930 935 940 Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Lys Ser 945 950 955 960 Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg 965,970,975 Glu Ile Asn Asn Tyr His Ala His Asp Ala Tyr Leu Asn Ala Val 980,985,990 Val Gly Thr Ala Leu Ile Lys Tyr Pro Lys Leu Glu Ser Glu Phe 995 1000 1005 Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala 1010 1015 1020 Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe 1025 1030 1035 Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala 1040 1045 1050 Asn Gly Glu With Arg Lys Arg Pro Leu Glu Thr Asn Gly Glu 1055 1060 1065 Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val 1070 1075 1080 Arg Lys Will Be Met Pro Gln Val Asn Ile Val Lys Thr 1085 1090 1095 Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys 1100 1105 1110 Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro 1115 1120 1125 Light Light Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val 1130 1135 1140 Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys 1145 1150 1155 Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser 1160 1165 1170 Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys 1175 1180 1185 Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu 1190 1195 1200 Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly 1205 1210 1215 Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val 1220 1225 1230 Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser 1235 1240 1245 Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys 1250 1255 1260 His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys 1265 1270 1275 Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala 1280 1285 1290 Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn 1295 1300 1305 Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala 1310 1315 1320 Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser 1325 1330 1335 Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr 1340 1345 1350 Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp 1355 1360 1365 <210> 22 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Description of artificial sequence: Synthetic peptide <400> 22 Gly Gly Ser Gly 1 <210> 23 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> twenty three Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala 1 5 10 <210> twenty four <211> 16 <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> twenty four Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Ser 1 5 10 15 <210> 25 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic peptides <400> 25 Ser Gly Ser Glu Thr Pro Gly Thr Ser Glu Ser Ala Thr Pro Glu Gly 1 5 10 15 Gly Ser Gly Gly Ser 20 <210> 26 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 26 gccgaggtga agttcgaggg cgac 24 <210> 27 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 27 cctacggcgt gcagtgcttc agc 23 <210> 28 <211> 332 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 28 acgtaaacgg ccacaagttc agcgtgtccg gcgagggcga gggcgatgcc acctacggca 60 agctgaccct gaagttcatc tgcaccaccg gcaagctgcc cgtgccctgg cccaccctcg 120 tgaccaccct gacctacggc gtgcagtgct tcagccgcta ccccgaccac atgaagcagc 180 acgacttctt caagtccgcc atgcccgaag gctacgtcca ggagcgcacc atcttcttca 240 aggacgacgg caactacaag acccgcgccg aggtgaagtt cgagggcgac accctggtga 300 accgcatcga gctgaagggc atcgacttca ag 332 <210> 29 <211> 295 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 29 gtccggcgag ggcgagggcg atgccaccta cggcaagctg accctgaagt tcatctgcac 60 caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca 120 gtgcttcagc cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc 180 cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagacccg 240 cgtcgagggc gacaccctgg tgaaccgcat cgagctgaag ggcatcgact tcaag 295 <210> 30 <211> 158 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 30 tccggcgagg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc 60 accggcaagc tgcccgtgcc ctggcccacc ctcgtgacca ccctgacgag ggcgacaccc 120 tggtgaaccg catcgagctg aagggcatcg acttcaag 158 <210> 31 <211> 285 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 31 tccggcgagg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc 60 accggcaagc tgcccgtgcc ctggcccacc ctcgtgaaca ccctgaccta cgtgcagtgc 120 ttcagccgct accccgacca catgaagcag cacgacttct tcaagtccgc catgcccgaa 180 ggctacgtcc aggagcgcac catcttcttc aaggacgacg gcaactacaa gttcgagggc 240 gacaccctgg tgaaccgcat cgagctgaag ggcatcgact tcaag 285 <210> 32 <211> 301 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequence: Synthetic oligonucleotide <400> 32 ccggcgaggg cgagggcgat gccacctacg gcaagctgac cctgaagttc atctgcacca 60 ccggcaagct gcccgtgccc tggcccaccc tcgtgaccac cctgacctac gtgcagtgct 120 tcagccgcta ccccgaccac atgaagcagc acgacttctt caagtccgcc atgcccgaag 180 gctacgtcca ggagcgcacc atcttcttca aggacgacgg caactacaag acccgcgccg 240 aggtgaagtt cgagggcgac accctggtga accgcatcga gctgaagggc atcgacttca 300 a 301 <210> 33 <211> 156 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 33 tccggcgagg gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc 60 accggcaagc tgcccgtgcc ctggcccacc ctcgtgacca ccctgaccta cggacaccct 120 ggtgaaccgc atcgagctga agggcatcga cttcaa 156 <210> 34 <211> 197 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 34 gtaaacggcc acaagttcag cgtgcagtgc ttcagccgct accccgacca catgaagcag 60 cacgacttct tcaagtccgc catgcccgaa ggctacgtcc aggagcgcac catcttcttc 120 aaggacgacg gcaactacaa gacggcaact acaagttcga gggcgacacc ctggtgaacc 180 gcatcgagct gaagggc 197 <210> 35 <211> 283 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 35 ccacaagttc agcgtgtccg gcgagggcga gggcgatgcc acctacggca agctgaccct 60 gaagttcatc tgcaccaccg gcaagctgcc cgtgccctgg cccaccctcg tgaccaccct 120 gacctacggc gtgcagtgct tcagccgcta ccccgaccac atgaagcagc acgacttctt 180 caagtccgcc atgcccgaag gctacgtcca ggagcgcacc atcttcttca aggacgacgg 240 caactacaag acaccgcatc gagctgaagg gcatcgactt caa 283 <210> 36 <211> 175 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 36 ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg ccacctacgg caagctgacc 60 ctgaagttca tctgcaccac cggcaccatc aaggacgacg gcaactacaa gacccgcgcc 120 gaagttcgag ggcgacaccc tggtgaaccg catcgagctg aagggcatcg acttc 175 <210> 37 <211> 291 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 37 taaacggcca caagttcagc gtgtccggcg agggcgaggg cgatgccacc tacggcaagc 60 tgaccctgaa gttcatctgc accaccggca agctgcccgt gccctggccc accctcgtga 120 ccaccctgac ctacggcgtg cagtgcttca gccgctaccc cgaccacatg aagcagcacg 180 acttcttcaa gtccgccatg cccgaaggct acgtccagga gcgcaccatc ttcttcaagg 240 acgacggcaa ctacaagacc tggtgaaccg catcgagctg aagggcatcg a 291 <210> 38 <211> 314 <212> DNA <213> Artificial Sequence <220> <223> Description of artificial sequence: Synthetic oligonucleotide <400> 38 cacaagttca gcgtgtccgg cgagggcgag ggcgatgcca cctacggcaa gctgaccctg 60 aagttcatct gcaccaccgg caagctgccc gtgccctggc ccaccctcgt gaccaccctg 120 acctacggcg tgcagtgctt cagccgctac cccgaccaca tgaagcagca cgacttcttc 180 aagtccgcca tgcccgaagg ctacgtccag gagcgcacca tcttcttcaa ggacgacggc 240 aactacaaga cccgcgccga ggttcgaggg cgacaccctg gtgaaccgca tcgagctgaa 300 gggcatcgac ttca 314 <210> 39 <211> 316 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 39 taaacggcca caagttcagc gtgtccggcg agggcgaggg cgatgccacc tacggcaagc 60 tgaccctgaa gttcatctgc accaccggca agctgcccgt gccctggccc accctcgtga 120 ccaccctgac ctacggcgtg cagtgcttca gccgctaccc cgaccacatg aagcagcacg 180 acttcttcaa gtccgccatg cccgaaggct acgtccagga gcgcaccatc ttcttcaagg 240 acgacggcaa ctacaagacc cgcgccgagg gcgacaccct ggtgaaccgc atcgagctga 300 agggcatcga cttcaa 316 <210> 40 <211> 318 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 40 aaacggccac aagttcagcg tgtccggcga gggcgagggc gatgccacct acggcaagct 60 gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg ccctggccca ccctcgtgac 120 caccctgacc tacgtgcagt gcttcagccg ctaccccgac cacatgaagc agcacgactt 180 cttcaagtcc gccatgcccg aaggctacgt ccaggagcgc accatcttct tcaaggacga 240 cggcaactac aagacccgcg ccgaggtgaa gttcgagggc gacaccctgg tgaaccgcat 300 cgagctgaag ggcatcga 318 <210> 41 <211> 185 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 41 acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac ggcaagctga 60 ccctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc ctcgtgacca 120 ccctgaccta cgtgaagttc gagggcgaca ccctggtgaa ccgcatcgag ctgaagggca 180 tcgac 185 <210> 42 <211> 180 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 42 aaacggccac aagttcagcg tgtccggcga gggcgagggc gatgccacct acggcaagct 60 gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg ccctggccca ccctcgtgac 120 caccctgacc tacgtgaagt tcgagggcga caccctggtg aaccgcatcg agctgaaggg 180 <210> 43 <211> 242 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (132)..(132) <223> a, c, t, g, unknown or other <220> <221> Modified bases <222> (153)..(153) <223> a, c, t, g, unknown or other <220> <221> Modified bases <222> (174)..(174) <223> a, c, t, g, unknown or other <400> 43 aaacggccac aagttcagcg tgtccggcga gggcgagggc gatgccacct acggcaagct 60 gaccctgaag ttcatctgca ccaccggcaa gctgcccgtg ccctggccca cccttccgcc 120 atgcccgaag gntacgtcca ggagcgcacc atnttcttca aggacgacgg caantacaag 180 acccgcgccg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga 240 ct 242 <210> 44 <211> 175 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 44 caccctgacc tacggcgtgc agtgcttcag ccgctacccc gaccacatga agcagcacga 60 cttcttcaag tccgccatgc ccgaaggcta cgtccaggag cgcaccatct tcttcaagga 120 cgacggcaac tacaagaccc gcgccgaggt gaagttcgag ggcgacaccc tggtg 175 <210> 45 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 45 caccctgacc tacgtgaagt tcgagggcga caccctggt 39 <210> 46 <211> 161 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 46 caccctgacc tacggcgtgc agtgcttcag ccgctacccc gaccacatga agcagcacga 60 cttcttcaag tccgccatgc ccgaaggcta cgtccaggag cgcaccatct tcttcaagga 120 cgacggcaac tacaagaccc gcgccgaggg cgacaccctg g 161 <210> 47 <211> 145 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 47 caccctgacc tcagccgcta ccccgaccac atgaagcagc acgacttctt caagtccgcc 60 atgcccgaag gctacgtcca ggagcgcacc atcttcttca aggacgacgg caactacaag 120 acccgcgccg aggcgacacc ctggt 145 <210> 48 <211> 153 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 48 ttattataca tcggagccct gccaaaaaat caatgtgaag caaatcgcag cccgcctcct 60 gcctccgctc tactcactgg tgttcatctt tggttttgtg ggcaacatgc tggtcatcct 120 catcctgata aactgcaaaa ggctgaagag cat 153 <210> 49 <211> 113 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 49 ttattataca tcggagccct gccaaaaaat caatgtgaag caaatcgcag cccgcctccg 60 ctctactcac tggtgttcat ctttggtttt gtgggcaaca tgctggtcat cct 113 <210> 50 <211> 70 <212> DNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 50 ttattataca tcggagccct gccaaaaaat caatgtgaag caaatcgcag cccgcatgct 60 ggtcatcctc 70 <210> 51 <211> 62 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 51 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60 cg 62 <210> 52 <211> 54 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <220> <221> Modified bases <222> (1)..(20) <223> a, c, u or g, and this region may include 17-20 nucleotides, some of which may be missing <400> 52 nnnnnnnnnn nnnnnnnnnn guuuuagagc uagaaauagc aaguuaaaau aagg 54 <210> 53 <211> 28 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 53 guucacugcc guauaggcag cuaagaaa 28 <210> 54 <211> 20 <212> RNA <213> Artificial sequence <220> <223> Description of artificial sequences: synthetic oligonucleotides <400> 54 guucacugcc guauaggcag 20 BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 is a schematic illustrative construct used for the following initial multiplexing experiments:
[0039] 1+2: direct repeat crRNA array and Cas9, with separate tracrRNA
[0040] 3+4: short crRNA array separated by Csy4 site, with Csy4, Cas9, and separate tracrRNA
[0041] 5+6: full-length chimeric gRNA separated by Csy4 site.
[0042] 7: nls-FLAG-tagged Cas9
[0043] Figure 2 It is shown in the expression Figure 1 Column chart of the experimental results in the cells of the constructs shown in. Csy4 site + complete gRNA (constructs 5 and 6) is the most effective multiple framework.
[0044] Figure 3 It is an exemplary standard and a gRNA framework based on multiple Csy4, and a schematic overview and comparison of the transcripts they produce. Note that Csy4 enables the use of RNA Pol II promoter (such as CAG) as a substitute for U6, which is a kind of RNA Pol III promoter.
[0045] Figure 4It is a bar graph showing that in human cells, Csy4 cleavage produces truncated recognition sites of gRNA with higher activity. The processing of the truncated site also leaves a clean 5' end, effectively removing the 5'G restriction to the gRNA target sequence imposed by the U6 promoter.
[0046] Figure 5A -C is a sequence showing evidence of 2-target multiplexing edited in a single human cell. A single deletion was observed at either site 2 or 3 of interest. For sites 2 and 3, multiple deletions on the same sequence were observed. Deletions spanning sites 2 and 3 were also observed.
[0047] Figure 6 is a schematic diagram showing successful multiplex expression of three gRNAs using a Csy4-based system.
[0048] Figure 7 It is to show that by Csy4, the gRNA excised from the mRNA transcribed by RNA Pol II can effectively recruit the Cas9 nuclease to the specific target in human cells. In these experiments, gRNA is expressed in the longer mRNA transcript made from the RNA Pol II CAG promoter.
[0049] Details
[0050] A potential advantage of the Cas9 system is the ability to recruit nuclease activity or heterologous effector domains to more than one genomic locus or target site in a cell. However, such multiple applications require the ability to effectively express more than one gRNA in a cell. For mammalian cells, RNA polymerase III promoters (such as U6 promoters) have been used to express single short gRNAs. Previous attempts to express multiple gRNA components from a single transcript in human cells have not been proven to be effective.
[0051] For the Cas9 system, another desirable ability is to produce inducible versions of the components and achieve tissue-specific expression of the components. Inducible and / or tissue-specific RNA polymerase II promoters have been described previously. However, although Cas9 or dCas9 proteins can be expressed from such RNA pol II promoters, short, defined gRNAs cannot be expressed in this way because the start and stop sites of transcription from RNA pol II are imprecise. In fact, all gRNAs to date have been expressed from RNA polymerase III promoters, and these promoters are ideally suited for the expression of short RNAs.
[0052] As demonstrated herein, Csy4 is a kind of endoribonuclease, and this endoribonuclease recognizes short RNA hairpin sequence, can be used for cutting off the multifunctional gRNA (generated from RNA pol II or III promoter) box encoded on single longer RNA transcript, and each gRNA in this longer RNA transcript is separated by Csy4 cleavage site. Functional gRNA can be successfully cut from longer RNA transcript, and these RNA transcripts are expressed from RNA pol II promoter.
[0053] gRNA / Csy4 polycassette
[0054] Therefore, described herein is a DNA molecule encoding a longer RNA transcript, which is referred to as a polybox herein, and the polybox includes two or more gRNA sequences, wherein each gRNA flank is a Csy4 cleavage sequence. The DNA molecule may also include a promoter, and may optionally include one or more other transcriptional regulatory sequences, such as enhancers, silencers, insulators, and poly-A sequences. See, e.g., Xu et al., Gene, July 11, 2001; 272 (1-2): 149-56.
[0055] Promoter
[0056] A plurality of promoters that can be used for the methods of the present invention are known in the art. In some embodiments, the promoter is a PolII or Pol III promoter, preferably a Pol II promoter. Different Pol II promoters have been described, and these Pol II promoters can be used for the compositions and methods of the present invention, including CAG promoters (see, e.g., Alexopoulou et al., BMC Cell Biology 9:2, 2008; Miyazaki et al., Gene 79(2):269–77 (1989); Niwa et al., Gene 108(2):193–9 (1991)); additional promoters include EF1A, CAGGS, PGK, UbiC and CMV promoters, together with tissue-specific promoters, such as, among others, B29, desmin, endoglin, FLT-1, GFPA, SYN1; the sequences of a plurality of promoters are known in the art. For example, the CMV and PGK promoters can be amplified from pSicoR and pSicoR PGK, respectively (Ventura et al., Proc Natl Acad Sci USA 101: 10380–10385 (2004)), the UbiC promoter can be amplified from pDSL_hpUGIH (ATCC), the CAGGS promoter can be amplified from pCAGGS (BCCM), and the EF1A promoter can be amplified from the pEF6 vector (Invitrogen). The Pol II core promoter is described in Butler and Kadonaga, Genes & Dev. 16: 2583-2592 (2002). Excision of the gRNA from a larger transcript driven by Pol II expression enables one to produce a gRNA with any nucleotide at the most 5'-position (standard expression from U6 or other RNA polymerase III promoters restricts the identity of this nucleotide).
[0057] In some embodiments, tissue-specific promoters are used, and short, defined gRNA sequences can be processed away from RNA-Pol II transcripts.
[0058] A number of Pol III promoters are known in the art, including the U6 small nuclear (sn) RNA promoter, the 7SK promoter, and the H1 promoter. See, e.g., Ro et al., BioTechniques 38(4):625–627 (2005).
[0059] Guide RNA
[0060] By using a single gRNA carrying at least 17-20 nt at its 5' end complementary to the genomic DNA target site, the Cas9 nuclease can be directed to a specific genomic target of at least 17-20 nt carrying an additional proximal protospacer adjacent motif (PAM) of the sequence NGG.
[0061] Thus, the compositions described herein can include a sequence encoding a single guide RNA (sgRNA) comprising a crRNA fused to a normally trans-encoded tracrRNA, such as a single Cas9 guide RNA, as described in Mali et al., Science 2013 Feb 15;339(6121):823-6, wherein the sequence at the 5' end is complementary to 17-20 nucleotides (nt) of the target sequence immediately 5' of a protospacer adjacent motif (PAM), such as NGG, NAG or NNGG.
[0062] Methods for designing and expressing guide RNAs are known in the art. Guide RNAs are generally classified into two different systems: 1) System 1 uses separate crRNAs and tracrRNAs that function together to guide cleavage with Cas9; and 2) System 2 uses chimeric crRNA-tracrRNA hybrids of two separate guide RNAs combined in a single system (Jinek et al. 2012). The tracr-RNA can be variably truncated, and a range of lengths that function in both the separate system (system 1) and the chimeric gRNA system (system 2) have been shown. See, e.g., Jinek et al., Science 2012;337:816–821; Mali et al., Science 2013 Feb 15;339(6121):823-6; Cong et al., Science 2013 Feb 15;339(6121):819-23; and Hwang and Fu et al., Nat Biotechnol. 2013 Mar;31(3):227-9; Jinek et al., Elife 2, e00471 (2013). For System 2, in general, longer length chimeric gRNAs have shown greater on-target activity, however, the relative specificity of gRNAs of different lengths is currently undefined, and thus in certain instances it may be desirable to use shorter gRNAs. In some embodiments, gRNA is complementary to a region within about 100-800bp upstream of the transcription start site, such as about 500bp upstream of the transcription start site, including the transcription start site, or about 100-800bp downstream of the transcription start site, such as about 500bp. In some embodiments, a vector (e.g., plasmid) encoding more than one gRNA is used, such as a plasmid encoding 2,3,4,5, or more gRNAs, which are directed to different sites in the same region of the target gene. Additional guide RNAs and methods for increasing the specificity of genome editing are described in provisional patent application serial number 61 / 838,178 entitled INCREASING SPECIFICITY FORRNA-GUIDED GENOME EDITING.
[0063] In some embodiments, the gRNA comprises or consists of the following sequence:
[0064] (X 17-20 )GUUUUAGAGCUAUGCUGUUUUG(X N )(SEQ ID NO:4);
[0065] (X 17-20 )GUUUUAGAGCUA (SEQ ID NO:5);
[0066] (X 17-20 )GUUUUAGAGCUAUGCUGUUUUG(SEQ ID NO:6);
[0067] (X 17-20 )GUUUUAGAGCUAUGCU(SEQ ID NO:7);
[0068] (X 17-20 )GUUUUAGAGCUAGAAAAUAGCAAGUUAAAAUAAGGCUAGUCCG
[0069] (X N (SEQ ID NO:8);
[0070] (X 17-20 )GUUUUAGAGCUAUGCUGAAAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUC(X N (SEQ ID NO:9);
[0071] (X 17-20 (X N )(SEQ ID NO:10);
[0072] (X 17-20 (X N (SEQ ID NO:11),
[0073] (X 17-20 )GUUUAAGAGCUAGAAAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAAGUGGCACCGAGUCGGUGC(SEQ ID NO:12);
[0074] (X 17-20)GUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 13); or
[0075] (X 17-20 )GUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC (SEQ ID NO: 14),
[0076] Where X 17-20 A target sequence that is complementary to a complementary strand of at least 17-20 consecutive nucleotides of a target sequence (although in some embodiments, this region of complementarity may be greater than 20 nt, such as 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more nt, such as 17-30 nt), preferably immediately 5' to the protospacer sequence adjacent motif (PAM), such as NGG, NAG, or NNGG. N is any sequence, wherein N (in the RNA) can be 0-300 or 0-200, such as 0-100, 0-50, or 0-20, which does not interfere with the binding of the ribonucleic acid to Cas9. In some embodiments, the RNA includes one or more Us, such as 1 to 8 or more Us (e.g., U, UU, UUUU, UUUUU, UUUUUUU, UUUUUUUU), at the 3' end of the molecule due to the optional presence of one or more Ts used as termination signals to terminate RNA PolIII transcription. In some embodiments, the RNA includes one or more, such as up to 3, such as one, two, or three, or more additional nucleotides at the 5' end of the RNA molecule that are not complementary to the target sequence. Optionally, one or more of the RNA nucleotides are modified, such as locked (2'-O-4'-C methylene bridge), 5'-methylcytidine, 2'-O-methyl-pseudouridine, or wherein the ribose phosphate backbone has been replaced by a polyamide chain, such as sequence X 17-20 One or more of the nucleotides in sequence X N , or replace one or more nucleotides in any sequence of the gRNA.
[0077] For example, in some embodiments, the chimeric guide RNA described in Jinek et al. (Science). 337(6096):816-21 (2012) can be used, for example,
[0078] (X 17-20) GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCG (SEQ ID NO: 8); (X 17-20) GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGG (SEQ ID NO: 9); In some embodiments, an sgRNA carrying a 5′-terminal 17-20 nucleotide sequence complementary to the target DNA sequence and a 3′-terminal stem-loop structure of 42 nucleotides necessary for Cas9 binding (described in Jinek et al., Elife. 2: e00471 (2013)) is used, for example (X 17-20) GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCG (SEQ ID NO: 8).
[0079] In some embodiments, the guide RNA includes one or more adenine (A) or uracil (U) nucleotides on the 3' end.
[0080] Although the examples described herein utilize a single gRNA, these methods can also be used with dual gRNAs (e.g., crRNA and tracrRNA found in naturally occurring systems). In this case, a single tracrRNA will be used in conjunction with multiple different crRNAs expressed using the present system, such as the following (note that for RNA, T should be understood as U here):
[0081] crRNA sequence: X 17-20 -GTTTTAGAGCTAGAAA(SEQ ID NO:15)
[0082] tracrRNA sequence: TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC (SEQ ID NO: 16). In this case, in the methods and molecules described herein, crRNA is used as a guide RNA, and tracrRNA can be expressed from the same or different DNA molecules.
[0083] In addition, although guide RNAs having complementary sequences of 17-20 nucleotides are exemplified herein, in some embodiments, longer sequences, such as 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more nt, such as 17-30 nt instead of 17-20 nt, can be used.
[0084] Csy4 cleavage sequence
[0085] In the methods and compositions described herein, the Csy4 cleavage sequence is inserted into this DNA molecule so that each guide RNA flank is a cleavage sequence, wherein one or at least one cleavage sequence is between each guide RNA. Exemplary Csy4 cleavage sequence includes GTTCACTGCCGTATAGGCAG (20nt of brachymemma) (SEQ ID NO:1) and GTTCACTGCCGTATAGGCAGCTAAGAAA (complete 28nt) (SEQ ID NO:2). As demonstrated herein, in human cells, it is more effective to use the Csy4 cleavage site (SEQ ID NO:1) of brachymemma compared with using the standard site. As known to the inventors of the present invention, this is the first proof of utilizing Csy4 activity in human cells.
[0086] Functional Csy4 enzyme sequence
[0087] In the methods described herein, a functional Csy4 enzyme capable of cleaving transcripts at the Csy4 cleavage site was also expressed in the cell.
[0088] Exemplary Csy4 sequences are from Csy4 homologs, and these Csy4 homologs are from Pseudomonas aeruginosa UCBPP-PA14 (Pa14), Yersinia pestis AAM85295 (Yp), Escherichia coli UTI89 (Ec89), Dichelobacternodosus VCS1703A (Dn), Acinetobacter baumannii AB0057 (Ab), Moritella sp. PE36 (MP1, MP01), Shewanella W3-18-1 (SW), Pasteurella multocida septicaemia subspecies Pm70 (Pm), Pectobacterium wasabiae) (Pw), and Erwinia chrysanthemi (Dickeyadadantii) Ech703 (Dd), are listed in Haurwitz et al., Science (Science) 329 (5997): 1355–1358 (2010) Figure S6. In a preferred embodiment, Csy4 is from Pseudomonas aeruginosa.
[0089] In certain embodiments, Csy4 is also used to covalently connect heterologous effector domains to gRNA. Csy4 is considered to be a single convertase, and retains binding to its target hairpin sequence after cutting (Sternberg et al., RNA. April 2012; 18 (4): 661-72). Therefore, it is expected that Csy4 retains the 3' end of the gRNA bound to each cut. Because as demonstrated herein, the gRNA cut seems to function in human cells, but the presence of this Csy4 protein at the 3' end of gRNA does not seem to affect the ability of gRNA to compound with Cas9 and guide Cas9 activity. Therefore, it is assumed that these gRNA-Csy4 fusions will also be able to guide the Cas9 mutants carrying mutations, which inactivate their catalytic nuclease activity (dCas9 protein). Therefore, people can fuse heterologous functional domains (HFD) to Csy4 (Csy4-HFD), and then dCas9:sgRNA:Csy4-HFD complexes can guide such domains to specific genomic loci. Examples of such HFDs may include other nuclease domains, such as domains from FokI, transcriptional activators, or repressor proteins, or other domains that modify histone or DNA methylation status.
[0090] Csy4-HFD is produced by fusing a heterologous functional domain (e.g., a transcriptional activation domain, such as from VP64 or NF-κBp65) to the N-terminus or C-terminus of Csy4, with or without an intervening linker, such as a linker of about 5-20 or 13-18 nucleotides. The transcriptional activation domain can be fused to the N or C-terminus of Csy4. In addition to the transcriptional activation domain, other heterologous functional domains as known in the art (e.g., transcriptional repressors (e.g., KRAB, SID, and other repressors) or silencers, such as heterochromatin protein 1 (HP1, also referred to as swi6), such as HP1α or HP1β; proteins or peptides that can recruit long noncoding RNAs (lncRNAs) fused to fixed RNA binding sequences, such as those bound by MS2 coat proteins, endoribonucleases Csy4, or λN proteins; enzymes that modify the methylation state of DNA (e.g., DNA methyltransferases (DNMTs) or TET proteins); or modified histone subunits An enzyme (e.g., histone acetyltransferase (HAT), histone deacetylase (HDAC), histone methyltransferase (e.g., for methylation of lysine or arginine residues), or histone demethylase (e.g., for demethylation of lysine or arginine residues). Multiple sequences of such domains are known in the art, such as domains that catalyze the hydroxylation of methylated cytosine in DNA. Exemplary proteins include the ten-eleven translocation (TET) 1-3 family, enzymes that convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) in DNA. See, e.g., WO / 2014 / 144761.
[0091] The sequences of human TET1-3 are known in the art and are shown in the table below:
[0092]
[0093] * Variant (1) represents the longer transcript and encodes the longer isoform (a). Variant (2) differs in the 5'UTR and in the 3'UTR as well as the coding sequence compared to variant 1. The resulting isoform (b) is shorter and has a different C-terminus compared to isoform a.
[0094] In some embodiments, all or a portion of the full-length sequence of a catalytic domain may be included, such as a catalytic module including a cysteine-rich stretch and a 2OGFeDO domain encoded by seven highly conserved exons, such as the Tet1 catalytic domain including amino acids 1580-2052, Tet2 including amino acids 1290-1905, and Tet3 including amino acids 966-1678. See, e.g., Iyer et al., Cell Cycle. 2009 Jun 1; 8(11): 1698-710. Figure 1 Electronic publication 27 June 2009 illustrates an alignment of key catalytic residues in all three Tet proteins, and supplementary material therefor (available at ftp site ftp.ncbi.nih.gov / pub / aravind / DONS / supplementary_material_DONS.html) for full-length sequences (see, e.g., seq 2c); in some embodiments, the sequence includes amino acids 1418-2136 of Tet1 or the corresponding region in Tet2 / 3.
[0095] Other catalytic modules may, for example, be derived from the protein identified by Iyer et al., 2009.
[0096] In certain embodiments, fusion protein includes the connexon between Csy4 and heterologous functional domain.The connexon that can be used for these fusion proteins (or between the fusion proteins in the structure connected) can include any sequence that does not interfere with the function of fusion protein.In a preferred embodiment, the connexon is short, such as 2-20 amino acid, and is typically flexible (i.e. including amino acid with high degree of freedom, such as glycine, alanine and serine).In certain embodiments, the connexon includes one or more units composed of GGGS (SEQ ID NO:3) or GGGGS (SEQ ID NO:17), such as two, three, four or more repetitions of GGGS (SEQ ID NO:3) or GGGGS (SEQ ID NO:17) units.Other connexon sequences can also be used, such as GGS, GGSG (SEQ ID NO:22), SGSETPGTSESA (SEQ ID NO:23), SGSETPGTSESATPES (SEQ ID NO:24) or SGSETPGTSESATPEGGSGGS (SEQ ID NO:25).
[0097] Cas9
[0098] In the methods described here, Cas9 is also expressed in the cells. A variety of bacteria express Cas9 protein variants. The Cas9 from Streptococcus pyogenes is currently the most commonly used; some other Cas9 proteins have high levels of sequence identity to the S. pyogenes Cas9 and use the same guide RNA. Other Cas9s are more diverse, use different gRNAs, and also recognize different PAM sequences (a 2-5 nucleotide sequence specified by the protein adjacent to the sequence specified by the RNA). Chylinski et al. classified Cas9 proteins from a large group of bacteria (RNA Biol. 10:5, 1–12; 2013) and in their supplement Figure 1A large number of Cas9 proteins are listed in Supplementary Table 1, which are incorporated herein by reference. The constructs and methods described herein may include the use of any of those Cas9 proteins, and their corresponding guide RNAs or other compatible guide RNAs. In Cong et al. (Science 39, 819 (2013)), Cas9 from the thermophilic Streptococcus LMD-9 CRISPR1 system has been shown to function in human cells. In addition, Jinek et al. showed that in vitro, Cas9 orthologs from thermophilic Streptococcus and Listeria innocua (but not from Neisseria meningitidis or Campylobacter jejuni, which may use different guide RNAs) can be guided by dual S. pyogenes gRNAs to cut target plasmid DNA, although with slightly reduced efficiency.
[0099] In some embodiments, the present system utilizes a Cas9 protein from Streptococcus pyogenes, as encoded in bacteria, or codon optimized for expression in mammalian cells. An exemplary sequence (residues 1-1368) of Streptococcus pyogenes Cas9 fused to an HA epitope (amino acid sequence DAYPYDVPDYASL (SEQ ID NO: 18)) and a nuclear localization signal (amino acid sequence PKKKRKVEDPKKKRKVD (SEQ ID NO: 19)) is as follows:
[0100]
[0101]
[0102] See Jinek et al., 2013, supra.
[0103] In some embodiments, a Cas9 sequence comprising one of the D10A and H840A mutations is used to render the nuclease a nickase, or a Cas9 sequence comprising both the D10A and H840A mutations is used to render the nuclease portion of the protein catalytically inactive. The sequence of a catalytically inactive Streptococcus pyogenes Cas9 (dCas9) that can be used in the methods and compositions described herein is as follows; mutations are in bold and underlined.
[0104]
[0105]
[0106] See, e.g., Mali et al., 2013, supra; and Jinek et al., 2012, supra. Alternatively, Cas9 can be a dCas9-heterofunctional domain fusion (dCas9-HFD), as described in U.S. Provisional Patent Application entitled RNA-GUIDED TARGETING OF GENETIC AND EPIGENOMIC REGULATORY PROTEINS TO SPECIFIC GENOMIC LOCI, filed on June 21, 2013, and assigned serial number 61 / 838,148, and in PCT / US 2014 / 027335.
[0107] As described herein, Cas9 can be expressed from an expression vector, such as an extrachromosomal plasmid or viral vector that includes a sequence encoding Cas9, such as a Cas9 cDNA or gene; Cas9 can be expressed from an exogenous Cas9 cDNA or gene that has been integrated into the genome of the cell; Cas9 can be expressed from an mRNA encoding Cas9; Cas9 can be the actual Cas9 protein itself; or, in the case of non-mammalian cells, can be exogenous Cas9.
[0108] Expression system
[0109] Can use the nucleic acid molecule that comprises expression vector, for example, for the body or in vitro expression of Csy4 / guide RNA construct described herein.Be used to express the carrier (potentially, in inducible or tissue- / cell-type specific mode) of multiple gRNA and can be used for research and therapeutic application.
[0110] In order to use the fusion protein described herein and the poly guide RNA box, it may be desirable to express them from the nucleic acid encoding them. This can be done in a variety of ways. For example, the nucleic acid encoding the guide RNA box or Csy4 or Cas9 protein can be cloned into an intermediate vector for transformation into a prokaryotic cell or eukaryotic cell to replicate and / or express. The intermediate vector is typically a prokaryotic vector, such as a plasmid, or a shuttle vector, or an insect vector, for the storage or manipulation of the nucleic acid encoding the fusion protein or for the production of the fusion protein. The nucleic acid encoding the guide RNA or the fusion protein can also be cloned into an expression vector for administration to a plant cell, an animal cell, preferably a mammalian cell or a human cell, a fungal cell, a bacterial cell, or a protozoan cell.
[0111] In order to obtain expression, the sequence encoding guide RNA or fusion protein is typically subcloned into an expression vector comprising a promoter for guiding transcription. Suitable bacteria and eukaryotic promoters are well known in the art, and for example in Sambrook et al., Molecular Cloning, A Laboratory Manual (3rd Edition, 2001); Kriegler, Gene Transfer and Expression: Laboratory Manual (Gene Transfer and Expression: A Laboratory Manual) (1990); and Current Protocols in Molecular Biology (Ausubel et al., 2010). Bacterial expression systems for expressing engineered proteins are available, such as in Escherichia coli, Bacillus and Salmonella (Palva et al., 1983, Gene 22: 229-235). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.
[0112] A variety of suitable vectors are known in the art, such as viral vectors, including recombinant retroviruses, lentiviruses, adenoviruses, adenovirus-associated viruses, and herpes simplex virus 1, adenovirus-derived vectors, or recombinant bacteria or eukaryotic plasmids. For example, the expression construct may include: a coding region; a promoter sequence, such as a promoter sequence that limits expression to a selected cell type, a conditional promoter, or a strong general promoter; an enhancer sequence; untranslated regulatory sequences, such as a 5' untranslated region (UTR), a 3'UTR; a polyadenylation site; and / or an insulator sequence. Such sequences are known in the art, and the skilled person will be able to select a suitable sequence. See, e.g., Current methods in molecular biology Protocols in Molecular Biology) (Ausubel FM et al. (eds.) Greene Publishing Associates, (1989), sections 9.10-9.14 and other standard laboratory manuals. In some embodiments, expression can be restricted to specific cell types using tissue-specific promoters, as is known in the art.
[0113] As described above, the vector for expressing the guide RNA can include RNA Pol II or Pol III promoters to drive the expression of the guide RNA. These human promoters allow the expression of gRNA in mammalian cells after plasmid transfection. Alternatively, the T7 promoter can be used, for example, for in vitro transcription, and the RNA can be transcribed and purified in vitro. The promoter used to guide the expression of nucleic acid depends on the specific application. For example, typically, a strong constitutive promoter is used for the expression and purification of the fusion protein. In contrast, when the fusion protein is administered in vivo for gene regulation, a constitutive promoter or an inducible promoter can be used, depending on the specific use of the fusion protein. In addition, the preferred promoter for administering the fusion protein can be a weak promoter, such as HSV TK, or a promoter with similar activity. The promoter may also include elements that respond to transcriptional activation, such as hypoxia response elements, Gal4 response elements, lactose repressor response elements, and small molecule control systems, such as the tetracycline regulation system and the RU-486 system (see, e.g., Gossen & Bujard, 1992, Proc. Natl. Acad. Sci. USA, 89:5547; Oligino et al., 1998, Gene Ther., 5:491-496; Wang et al., 1997, Gene Ther., 4:432-441; Neering et al., 1996, Blood, 88:1147-55; and Rendahl et al., 1998, Nat. Biotechnol., 16:757-761).
[0114] In addition to the promoter, the expression vector typically comprises a transcription unit or expression cassette that contains all additional elements required for expression of the nucleic acid in a host cell (prokaryotic or eukaryotic). Thus, a typical expression cassette comprises a promoter operably linked to a nucleic acid sequence that encodes, for example, a fusion protein, and any signals required for, for example, efficient polyadenylation of the transcript, transcription termination, a ribosome binding site, or translation termination. Additional elements of the cassette may include, for example, enhancers, and intrinsic signals for heterologous splicing.
[0115] The specific expression vector for transporting genetic information into the cell is selected for the intended use of the fusion protein, and the intended use is, for example, expression in plants, animals, bacteria, fungi, protozoa, etc. Standard bacterial expression vectors include plasmids, such as pBR322-based plasmids, pSKF, pET23D, and commercially available tag fusion expression systems, such as GST and LacZ. The preferred tag fusion protein is maltose binding protein (MBP). Such tag fusion proteins can be used to purify engineered TALE repeat proteins. Epitope tags can also be added to recombinant proteins to provide a convenient method for separation, for monitoring expression, and for monitoring cellular and subcellular localization, such as c-myc or FLAG.
[0116] Expression vectors containing regulatory elements from eukaryotic viruses are commonly used for eukaryotic expression vectors, such as SV40 vectors, papillomavirus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009 / A+, pMTO10 / A+, pMAMneo-5, baculovirus pDSVE, and any other vectors that allow expression of proteins under the direction of the following promoters: SV40 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown to be effective for expression in eukaryotic cells.
[0117] Some expression systems have markers for selection of stably transfected cell lines, such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. High-yield expression systems are also suitable, such as using baculovirus vectors in insect cells with the fusion protein coding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.
[0118] Elements typically included in expression vectors also include a replicon that functions in E. coli, genes encoding antibiotic resistance to allow selection of bacteria harboring the recombinant plasmid, and unique restriction sites in nonessential regions of the plasmid to allow insertion of recombinant sequences.
[0119] Standard transfection methods are used to generate bacterial, mammalian, yeast, or insect cell lines that express large amounts of protein, which are then purified using standard techniques (see, e.g., Colley et al., 1989, J. Biol. Chem., 264: 17619-22; Guide to Protein Purification, in Methods in Enzymology, Vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells is performed according to standard techniques (see, e.g., Morrison, 1977, J. Bacteriol. 132:349-351; Clark-Curtiss & Curtiss, Methods in Enzymology 101:347-362 (Wu et al., eds., 1983)).
[0120] Any known procedure for introducing exogenous nucleotide sequences into host cells can be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, nuclear transfection, liposomes, microinjection, naked DNA, plasmid vectors, viral vectors, both additional and integrated, and any other well-known methods (see, for example, Sambrook et al., supra) for introducing cloned genomic DNA, cDNA, synthetic DNA or other exogenous gene materials into host cells. Only the specific genetic engineering procedures that can successfully introduce at least one gene into the host cell that can express the protein of selection need to be used.
[0121] In certain embodiments, Cas9 or Csy4 protein includes a nuclear localization domain that provides protein translocation to the nucleus. Several nuclear localization sequences (NLS) are known, and any suitable NLS can be used. For example, many NLS have multiple basic amino acids, referred to as bidirectional alkaline repeats (Garcia (Garcia)-Bustos (Bustos) et al., 1991, Biochemistry and Biophysics Journal (Biochim.Biophys.Acta), 1071: 83-101 in summary). The NLS comprising bidirectional alkaline repeats can be located in any part of the chimeric protein, and causes the chimeric protein to be positioned in the nucleus. In a preferred embodiment, the nuclear localization domain is integrated into the final fusion protein, because the final function of the fusion protein described herein will typically require the protein to be positioned in the nucleus. However, in the case where the protein has an inherent nuclear translocation function, it may not be necessary to add a separate nuclear localization domain.
[0122] The present invention includes vectors and cells comprising the vectors.
[0123] library
[0124] Also provided herein are combinatorial libraries of gRNAs, for example in inducible, tissue- or cell-type-specific multiplex vectors for research applications, such as for screening potential drug targets or for defining interactions at the genetic level.
[0125] How to use
[0126] The described methods can include expressing in a cell, or contacting a cell with a polycassette as described herein, plus a nuclease that can be guided by a shortened gRNA, for example, a Cas9 nuclease as described above, and a Csy4 nuclease as described above.
[0127] For modifying the expression of multiple exogenous genes at the same time, or for targeting multiple parts of a single gene, the described system is a useful and versatile tool. To achieve this, the current method requires the use of separate gRNA encoding transcripts for each site to be targeted. For multiple genome editing of cell populations, separate gRNAs are not optimal because it is impossible to guarantee that each cell will express each gRNA; using multiple transcripts, cells obtain a complex and uneven random mixture of gRNAs. However, the present system allows multiple gRNAs from a single transcript to be expressed, which allows multiple sites to be targeted in the genome by expressing multiple gRNAs. In addition, using a single transcript system, each cell should express all gRNAs with similar stoichiometry. Therefore, this system can be easily used to change the expression of a large number of genes at the same time, or for recruiting multiple Cas9 or HFD to a single gene, promoter, or enhancer. This ability has a wide range of applications, such as for basic biological research, where it can be used to study gene function, and manipulate the expression of multiple genes in a single pathway, and for synthetic biology, where it will enable researchers to generate circuits in cells that respond to multiple input signals. It is relatively easy for this technique to be implemented and suitable for multiple reuse, which would make it a broadly useful technique with many wide applications.
[0128] Method described herein comprises contacting cell with nucleic acid encoding the poly-gRNA box described herein for one or more genes and nucleic acid encoding Csy4 and Cas9, thereby adjusting the expression of the one or more genes.
[0129] Examples
[0130] The present invention is further illustrated in the following examples, which are not intended to limit the scope of the invention described in the claims.
[0131] Example 1. Multiplex editing using CRISPR / Cas9
[0132] Using CRISPR / Cas9 with arrays of crRNAs or sgRNAs expressed from a single transcript, three strategies were attempted with the goal of performing multiple edits:
[0133] 1. CrRNA array and Cas9 flanked by direct repeats, with separate tracrRNA
[0134] 2. Expressed by short crRNA array separated by Csy4 site, together with Csy4, Cas9 and separated tracrRNA
[0135] 3. Full-length single guide RNA (sgRNA) separated by Csy4 site
[0136] Each set of constructs ( Figure 1 The results are shown in Table 2. In the EGFP disruption array, even for a single target, constructs designed using strategies 1 and 2 showed the lowest activity; therefore further experiments (described below) focused on optimizing strategy 3.
[0137] Example 2. Multiplexed expression of highly active CRISPR guide RNAs from RNA polymerase II and III promoters in mammalian cells
[0138] exist Figure 3 Shown in, use Csy4 nuclease, for the schematic overview of the exemplary strategy of cutting gRNA from longer transcripts.In the initial test used to prove proof of concept, for the cutting in human cells, two versions of the RNA hairpin site of Csy4 cutting were tested.To achieve this, the gRNA flanking one of the two Csy4 cutting sites was expressed:
[0139] 1.GTTCACTGCCGTATAGGCAGCTAAGAAA (all 28nt) (SEQ ID NO: 2)
[0140] 2. GTTCACTGCCGTATAGGCAG (truncated 20 nt) (SEQ ID NO: 1)
[0141] The results showed that in mammalian cells, gRNAs flanked by truncated 20nt sequences at their 5' and 3' ends were more active than those flanked by longer 28nt sequences ( Figure 4). To the best of the inventors' knowledge, this is the first demonstration that Csy4 nuclease can be used to process RNA transcripts in living human cells. An important additional advantage of the 20nt truncation site is that, unlike the longer 28nt sequence, it does not leave any additional nucleotides on the 5' end of the gRNA processed from the longer transcript ( Figure 4 ). This enables the expression of gRNAs with any desired nucleotide at the 5'-most position. This is an improvement over expressing gRNAs from RNA polymerase III promoters that have a requirement for a specific nucleotide or nucleotides at the 5'-most position.
[0142] Using this system based on Csy4, the effective expression of two and three different gRNAs was demonstrated (Fig. 5 and 6). This method was used to express gRNA induction simultaneously in human cells, at the change at the expected site.
[0143] These results also demonstrate that this Csy4-based strategy can be used with gRNAs encoded on longer mRNAs produced by RNA Pol II promoters ( Figure 7 ). In these experiments, one of three different single gRNAs flanking the truncated Csy4 site was encoded on the mRNA produced by the CAG promoter (an RNA Pol II promoter). Figure 7 As shown in , in human cells, all three constructs were able to produce functional gRNAs that could direct the Cas9 nuclease, but only in the presence of Csy4. The levels of on-target Cas9 activity observed were comparable (although somewhat lower) to those observed when these gRNAs were expressed alone using a standard RNA Pol III promoter, or as Csy4-flanked transcripts from an RNA Pol III promoter ( Figure 7 ).
[0144] In summary, the results of the present invention demonstrate that: 1) up to three functional gRNAs can be generated from a single RNA pol III transcript when separated by Csy4 cleavage sites and in the presence of Csy4 in human cells, 2) multiple Csy4-processed gRNAs can be used to guide Cas9 nuclease to induce multiple changes in a single human cell, and 3) functional gRNAs flanked by Csy4 cleavage sites can be excised from longer mRNA transcripts made from RNA polymerase II promoters by Csy4 nuclease.
[0145] Other Implementations
[0146] It should be understood that although the present invention has been described in conjunction with its detailed description, the foregoing description is intended to illustrate rather than limit the scope of the present invention, which is defined by the scope of the appended claims. Other aspects, advantages and modifications are within the scope of the following claims.
Claims
1. A deoxyribonucleic acid (DNA) molecule comprising: Multiple sequences encoding crRNA, wherein each crRNA is flanked by at least one Csy4 cleavage sequence, the Csy4 cleavage sequence consisting of the sequence GTTCACTGCCGTATAGGCAG (SEQ ID NO: 1); and a sequence encoding tracrRNA; The crRNA sequence is: 17-20 )GTTTTAGAGCTAGAAA(SEQ ID NO:15); And the tracrRNA sequence is: TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACC GAGTCGGTGC (SEQ ID NO: 16); where X 17-20 It is a sequence that is complementary to the complementary strand of 17-20 consecutive nucleotides of the target sequence.
2. The DNA molecule of claim 1, operably linked to a promoter sequence.
3. A DNA molecule as described in claim 1 or 2, comprising two, three or more crRNA sequences.
4. The DNA molecule of claim 2, wherein the promoter sequence is an RNA polymerase II (Pol II) promoter or a Pol III promoter.
5. The DNA molecule of claim 2, wherein the promoter sequence is an RNA Pol II promoter.
6. The DNA molecule of claim 5, wherein the Pol II promoter is selected from the group consisting of: CAG, EF1A, CAGGS, PGK, UbiC, CMV, B29, desmin, endoglin, FLT-1, GFPA, and SYN1 promoters.
7. A DNA molecule comprising a promoter sequence linked to one, two, three or more cassettes comprising: A sequence encoding crRNA linked to a Csy4 cleavage site consisting of GTTCACTGCCGTATAGGCAG (SEQ ID NO: 1); and a sequence encoding tracrRNA; The crRNA sequence is: 17-20 )GTTTTAGAGCTAGAAA(SEQ ID NO:15); And the tracrRNA sequence is: TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCAC CGAGTCGGTGC (SEQ ID NO: 16); where X 17-20 It is a sequence that is complementary to the complementary strand of 17-20 consecutive nucleotides of the target sequence.
8. The DNA molecule of claim 7, comprising: A Pol II promoter, the Pol II promoter is operably connected to a first sequence encoding a first crRNA, the first sequence is connected to a Csy4 cleavage site, the Csy4 cleavage site is connected to a second sequence encoding a second crRNA, the second sequence is connected to a Csy4 cleavage site, the Csy4 cleavage site is connected to a third sequence encoding a third crRNA, and the third sequence is connected to the Csy4 cleavage site.
9. A DNA molecule as described in claim 7, comprising a crRNA sequence of 100nt.
10. DNA molecules as claimed in claim 1 or 7, further comprise the sequence of encoding functional Csy4 enzyme.
11. The DNA molecule of claim 1 or claim 7, wherein the target sequence is the target sequence immediately 5' to the protospacer adjacent motif (PAM).
12. The DNA molecule of claim 1 or claim 7, comprising one or more U at the 3' end of the molecule.
13. An RNA molecule encoded by the DNA molecule according to any one of claims 1 to 12.
14. A vector comprising the DNA molecule according to any one of claims 1 to 12.
15. carrier as claimed in claim 14, further comprises the sequence of encoding functional Csy4 enzyme.
16. A method for producing multiple crRNAs in a cell, the method comprising contacting the cell with an RNA molecule as described in claim 13 in vitro.
17. method as claimed in claim 16, wherein said cell is a mammalian cell and said cell also expresses exogenous functional Csy4 enzyme sequence.
18. A method for altering the expression of multiple target genes in a cell, the method comprising contacting the cell with a DNA molecule as described in any one of claims 1 to 12 or an RNA molecule as described in claim 13 in vitro, wherein each crRNA comprises a sequence complementary to at least 17 nt of the target gene.
19. A method for changing the expression of a target gene in a cell, the method comprising contacting the cell with a DNA molecule as described in any one of claims 1 to 12 or an RNA molecule as described in claim 13 in vitro, wherein each crRNA comprises a sequence complementary to at least 17 nt of the target gene.
20. Use of the DNA molecule of any one of claims 1 to 12 or the RNA molecule of claim 13 in the preparation of a medicament for altering the expression of multiple target genes in a cell, wherein each crNRA comprises a sequence complementary to at least 17 nt of the target gene.
21. Use of the DNA molecule of any one of claims 1 to 12 or the RNA molecule of claim 13 in the preparation of a medicament for altering the expression of a target gene in a cell, wherein each crNRA comprises a sequence complementary to at least 17 nt of the target gene.
22. The method of any one of claims 18-19 or the use of any one of claims 20-21, wherein each crRNA comprises a sequence complementary to at least 18 nt of the target gene.
23. The method of any one of claims 18-19 or the use of any one of claims 20-21, wherein each crRNA comprises a sequence complementary to at least 19 nt of the target gene.
24. The method of any one of claims 18-19 or the use of any one of claims 20-21, wherein each crRNA comprises a sequence complementary to at least 20 nt of the target gene.
Citation Information
Patent Citations
Oil collection tray
US20140027335A1
Light guide plate touch device
US20140028630A1
Image reading apparatus and image forming apparatus
US20140029068A1
Side-edge backlight module having non-uniformly sized backlight sections and design method thereof
US20140029304A1
Interface Substrate with Interposer
US20140035162A1
